• 제목/요약/키워드: drug side effects

검색결과 657건 처리시간 0.023초

N2 종격동 림프절 전이가 있는 제 III A 병기 비소세포폐암에 있어 수술전 동시화학방사선요법 후 폐적출술의 조기 성적 (Early Result of Surgical Resection after Pre-Operative Concurrent chemoradiotherapy for N2-Positive Stage IIIA NSCLC)

  • 차대원;김진국;심영목;김관민;박근칠;안용찬
    • Journal of Chest Surgery
    • /
    • 제33권8호
    • /
    • pp.662-668
    • /
    • 2000
  • Background: Many recent results of clinical trials show that pre-operative concurrent chemoradiotherapy and surgical resection could increase the survival of N2 positive stage IIIA non-small cell lung cancer. This study was performed to assess the feasibility, toxicity, and affect rates of concurrent chemoradiotherapy and surgical resection in N2 positive stage IIIA non-small cell lung cancer. Material and Method: Thirty-one patients who underwent preoperative concurrent chemoradiotherapy for N2 positive stage IIIA non-small-cell lung cancer from May 1997 to April 1999 were entered into the study. Mean age was 61 yrs(43∼70 yrs), There were 24 men and 7 women. The confirmation of N2 disease were achieved through mediastinoscopic biopsy(24) and CT scans(7). Induction was achieved by two cycles of cisplatin and etoposide(EP) plus concurrent chest radiotherapy to 45 Gy. Resections were done at 3 weeks after the complection of preoperative concurrent chemoradiotherapy. Resections were performed in 23 patients, excluding 5 refusals and 3 distant metastasis. Result: All patients were compled the thoracic radiotherapy except one who had distant metastasis. Twenty three patients were completed the planned 2 cycles of EP chemotherapy, and 8 patients were received only 1 cycle for severe side effects(6), refusal(1), and distant metastasis(1). There was one postoperative mortality, and the cause of death was ARDS. Three patients who had neutropenic fever and one patient who had radiation pneumonitis were required admission and treatment. Esophagitis was the most common acute side effect, but relatively well-tolerated in most patients. The complection rate of concurrent chemoradiotherapy was 74%, resection rate was 71%, pathologic complete remission rate was 13.6%, and pathologic down-staging rate was 68%. Conclusion: Morbidity related to each treatment was acceptable and many of the patients have benefited down staging of its disease. Further prospective, preferably randomized, clinical trials of larger scale may be warranted to confirm the actual benefit of preoperative concurrent chemoradiotherapy and surgical resection in N2-positive stage IIIA non-small cell lung cancer.

  • PDF

천연물 항암제제 임상시험 평가지표 개발연구 (Study on Development of Assessment Guideline and Endpoints for Clinical Trial with Antitumor Natural Products)

  • 남궁미애;장유성;정승기;김진성;윤성우;장기영;유화승;정면우;이성호;김성훈
    • 동의생리병리학회지
    • /
    • 제20권6호
    • /
    • pp.1678-1727
    • /
    • 2006
  • This study was perfromed to develop the assessment guideline and endpoints for clinical trial with anticancer herbal medicine. The botanical products used to humans for long time may be applied to phase 3 clinical trial after submitting the evidences for safety and efficacy of them or completion of basic requirement of phase 1 and phase 2 for safety confirmation and dose determination. Syndrome improvement was chiefly evaluated by Zubrod and karnofsky(%) methods. We suggest the general clinical trial assessment with botanical products, by following assessment points, that is, tumor size for 50 points, survival fate for 10 points, major syndromes for 40 points. It is recommendable that the each symptom of Qi deficiency syndrome, blood deficiency syndrome and Qi stagnation syndrome was allocated by assessment points, Similarly, the each symptom was given the assessment points according to the severity of symptom, for example, slight for 3 points, moderate for 2 points and severe for 1 point in hepatocelluar carcinoma and lung cancer. Then, the efficacy of botanical products was evaluated by the difference between pre-treatment and post-treatment. Asking the neoplastic patients of questionnaire on physical, emotional, cognitive, social and role subjects availability, three more syndromes (Fatigue, Pain and Nausea/Vomit), quality of life(QOL) will be evaluated by GLM statistics. In addition, in case of lung cancer, 13 questions will be asked by the EORTC QLQ-C13 forms. As the assessment of endpoints for efficacy to reduce side effects induced by chemotherapy and radiotherapy, the data of image scanning and hemato-urinalysis can be usefully applied on immune response, weight loss, indigestion, hemopoietic damage and injury of liver and kidney, while the changes of syndromes of side effect can be evaluated by differentiation methods of Qi and blood and five viscera. However, it is still necessary to determine the ratio between scientific analytical method and Oriental differentiation method as well as confirm the Oriental assessment endpoints by clinical trial. In addition, we suggest the continuous development of assessment endpoints on other carcinomas except of hepatocelluar carcinoma and lung cancer in future.

입원 환자의 섬망 치료에서 멜라토닌의 효과에 관한 후향적 연구 (Melatonin for Treatment of Delirium in Hospitalized Patients : Retrospective Trial)

  • 양정우;김종우;강원섭;이상민;김영종;백종우
    • 정신신체의학
    • /
    • 제26권2호
    • /
    • pp.112-118
    • /
    • 2018
  • 연구목적 섬망은 신체 질환과 같은 기저 의학적 상태의 변화에 의해 나타나는 뇌의 기능장애로 환자의 사망률을 높이고 치매의 위험도를 높이는 등 불량한 예후와 연관되어 있다. 기존 섬망의 치료에 주로 사용된 항정신병약제는 치료 효과에 대한 논란이 있으며 추체외로 부작용 등에 대한 우려가 있다. 따라서 수면 주기 조절 및 섬망 예방효과가 있는 것으로 알려진 멜라토닌 투여를 통해 섬망 호전 정도와 안전성을 조사하고자 하였다. 방 법 불면을 동반한 섬망 증상으로 정신건강의학과에 진료 의뢰되어 멜라토닌 2mg을 투여 받은 환자를 대상으로 의무기록을 통해 섬망 증상의 초기 중증도 및 멜라토닌 투여 후의 섬망 증상 변화 여부를 한국판 섬망 평가척도-98 개정판(K-DRS-R-98)과 CGI-S를 통해 확인하였으며 부작용을 검토하였다. 결 과 총 21명의 환자가 불면을 동반한 섬망 증상으로 멜라토닌을 투여받았다. K-DRS-R-98 심각도 점수는 투약 전 $15.24{\pm}2.64$에서 투약 후 $6.57{\pm}5.42$로 감소하였으며 CGI-S 점수는 $4.14{\pm}0.48$에서 $2.81{\pm}0.93$로 감소하였다(p<0.05). 의무기록 상 부작용은 관찰되지 않았다. 결 론 약물의 기전 상 추체외로 증상과 QTc연장 등의 문제를 유발하지 않는 멜라토닌의 사용은 보다 안정성을 강화하면서 불면에 대한 효과와 함께 섬망을 효과적으로 치료할 가능성을 제시할 것으로 생각된다.

Cytotoxic Effects on HL-60 Cells of Myosin Light Chain Kinase Inhibitor ML-7 Alone and in Combination with Flavonoids

  • Lee, Joong-Won;Kim, Yang-Jee;Choi, Young-Joo;Woo, Hae-Dong;Kim, Gye-Eun;Ha, Tae-Kyung;Lee, Young-Hyun;Chung, Hai-Won
    • Toxicological Research
    • /
    • 제25권4호
    • /
    • pp.181-188
    • /
    • 2009
  • Uncontrolled cell growth and increased cell proliferation are major features of cancer that are dependent on the stable structure and dynamics of the cytoskeleton. Since stable cytoskeleton structure and dynamics are partly regulated by myosin light chain kinase (MLCK), many current studies focused on MLCK inhibition as a chemotherapeutic target. As a potent and selective MLCK inhibitor, ML-7 [1-(5-iodonaphthalene-1-sulfonyl)-1 H-hexahydro-1,4-diazapine hydrochloride] is a promising candidate for an anticancer agent, which would induce apoptosis as well as prevents invasion and metastasis in certain types of cancer cells. This study assessed cytotoxic effects of ML-7 against HL-60 cells and therapeutic efficacy of ML-7 as a potential antileukemia agent. Trypan-blue exclusion assays showed dose- and time- dependent decreases in ML-7 treated HL-60 cells (p<0.05). Comet assays revealed a significant increase in DNA damage in HL-60 cells after treatment with $40{\mu}M$ ML-7 for 2h. Sub-G1 fractions, analyzed by flow cytometry increased in a dose-dependent manner, suggesting that ML-7 can induce apoptotic cell death in HL-60 cells. ML-7 was selectively cytotoxic towards HL-60 cells; not affecting normal human lymphocytes. That selective effect makes it a promising potential anti-leukemia agent. In addition, anticancer efficacy of ML-7 in combination with flavonoids (genistein or quercetin) or anticancer drugs (cisplatin or Ara-C) against HL-60 cells was assessed. Combination of ML-7 with flavonoids increased the anti-cancer effect of ML-7 to a greater extent than combination with the anticancer drugs. This implies that ML-7 in combination with flavonoids could increase the efficacy of anticancer treatment, while avoiding side effects cansed by conventional anticancer drug-containing combination chemotherapy.

A Literature Review of the Microneedle Therapy System for Hair Loss

  • Kim, Jeong-Hyon;Shim, Sung-Eun;Kim, Jun-Yeon;Kim, Ha-Na;Hwang, Ji-Min;Park, Kyeong-Ju;Jo, Min-Gi;Jang, Jun-Yeong;Kim, Jung-Hyun;Goo, Bonhyuk;Park, Yeon-Cheol;Seo, Byung-Kwan;Baek, Yong-Hyeon;Nam, Sang-Soo
    • Journal of Acupuncture Research
    • /
    • 제37권4호
    • /
    • pp.203-208
    • /
    • 2020
  • This literature review was designed to investigate the effects of the microneedle therapy system (MTS) on alopecia in experimental, and clinical studies. The MTS is acupuncture needling therapy delivered by a roller. A literature review of studies published before May 2020 was conducted using 9 online databases, and a total of 13 studies (4 in vivo studies and 9 clinical trials) were included. Most studies showed that the MTS was effective when used in combination with other treatments. In vivo studies reported an increased level of hair growth factors following treatment. Typically, 1.5 mm needles were used in the MTS treatment and photographic evaluation (by either camera or microscope) was reported in most studies. Oriental medicine research included 2 in vivo studies, which reported positive effects when combined with the MTS. There were no reported severe side effects. the MTS might be safe and has a drug delivery effect. Further studies need to be conducted regarding the frequency and needle length depending on the type of alopecia using Oriental and Western medicine.

임상에서 분리한 메치실린 내성 황색포도상구균에 대한 녹나무잎 추출물의 항균활성 (Synergistic Effects of Cinnamomum camphora Leaves Extract against Clinical Isolated Methicillin-resistant Staphylococcus aureus)

  • 차정단;최미래;고은실;황승미;강제란;오좌섭;박영진;정용환;전아림;최경민
    • 한국자원식물학회지
    • /
    • 제28권1호
    • /
    • pp.9-15
    • /
    • 2015
  • 메치실린내성 황색포도상구균(MRSA)은 가장 중요한 지역 사회 병원성 균주의 하나로서 항생제 내성 문제가 세계적으로 대두되고 있다. 감염 치료에 대한 부작용과 내성이 적은 새로운 항생제의 개발에 많은 관심과 연구가 필요하다. Cinnamomum camphora는 제주도에서 자생하는 녹나무과의 식물이다. 민간에서는 신경 쇠약, 간질, 방광염, 신우 신염, 당뇨, 암과 당뇨병 치료제로 이용되고 있다. 본 연구에서는 80% 에탄올을 이용하여 녹나무잎을 추출물하여 임상에서 분리한 메치실린 내성 균주에 대한 항균활성을 연구하였다. 그 결과 녹나무잎 추출물에서 높은 항균활성을 관찰 할 수 있었고, 항생제와의 병용처리 녹나무잎 추출물의 MIC와 MBC의 범위는 $156-313{\mu}g/ml$$313-625{\mu}g/ml$로 판독되었고, oxacillin의 병용처리의 범위는 $1288-256{\mu}g/ml$$128-512{\mu}g/ml$, 그리고 ampicillin의 병용처리 범위는 ${\mu}g/ml$$8-128{\mu}g/ml$로 판독되었다. 녹나무잎 추출물과 항생제의 병용처리는 MRSA 항균활성에 대한 상승효과가 높게 나타났다.

식물 유래 천연물의 인플루엔자에 대한 항바이러스 활성 (Antiviral Activity of Plant-derived Natural Products against Influenza Viruses)

  • 김선정;김예원;김주원;황유빈;김성현;장요한
    • 생명과학회지
    • /
    • 제32권5호
    • /
    • pp.375-390
    • /
    • 2022
  • 인수공통 호흡기바이러스인 인플루엔자바이러스 감염으로 인해 공중보건과 가축산업에 심각한 피해가 지속적으로 발생하고 있다. 인플루엔자 백신 접종을 통해 항원형이 일치하는 바이러스 감염에 대해 우수한 방어면역을 제공하고 있으나, 효과적인 바이러스 감염 제어에는 여전히 큰 공백이 존재하고 있다. 다양한 항원형을 갖는 바이러스에 동시방어가 가능한 범용인플루엔자백신 개발과 함께 바이러스 치료효과를 제공하는 항바이러스제의 개발도 중요한 접근법으로 고려되고 있다. 현재 널리 사용되고 있는 인플루엔자 항바이러스제의 불완전한 치료효과와 내성바이러스의 출현 등의 문제들로 인해 식물 유래 천연물의 항바이러스 활성에 대한 관심이 증가하고 있다. 특히, 현재 진행 중인 코로나-19 팬데믹은 범용적인 항바이러스 활성을 갖는 안전하고 효과적인 항바이러스제 개발의 필요성을 뚜렷이 보여준다. 본 리뷰는 현재까지 보고된 천연물의 항인플루엔자바이러스 활성을 요약하였다. 또한, 항바이러스 활성을 갖는 천연물의 바이러스 사멸활성과 면역증강활성을 이용하는 신규 백신개발과 면역증강제 개발 가능성에 대해서도 분석하였다.

주의력결핍과잉운동장애 아동에게 Methylphenidate-OROS 투여시 효용성과 안전성 및 부모 만족도를 평가하기 위한 다기관관찰연구 (AN OBSERVATIONAL MULTI-CENTER STUDY FOR EVALUATION OF EFFICACY, SAFETY AND PARENTAL SATISFACTION OF METHYLPHENIDATE-OROS IN CHILDREN WITH ADHD)

  • 김봉석;박은진
    • Journal of the Korean Academy of Child and Adolescent Psychiatry
    • /
    • 제16권2호
    • /
    • pp.279-285
    • /
    • 2005
  • 목적 : 이 연구에서는 장시간 약물작용이 지속되는 MPH-OROS를 주의력결핍과잉운동장애 아동에게 투여하여 그 효용성과 안전성 및 부모 만족도를 평가하려고 하였다. 방법 : 연구대상은 DSM-IV의 진단기준을 이용하여 임상적으로 ADHD로 진단 받은 569명의 아동으로 하였다. 이미 약물을 복용중이거나 약을 복용한 적이 없는 아동을 대상으로 이전 약물에서 MPH-OROS로 약물을 바꾸거나 처음으로 MPH-OROS를 복용하였다. 증상의 정도는 MPH-OROS 약물 사용 전과 사용 1주 및 3주에 한국어판 Conners 부모용 평가척도를 사용하여 평가하였다. 임상 호전은 Clinical Global Impression Severity of illness(CGI-S)를 사용하여 MPH-OROS 약물 복용 전과 복용 1주 및 3주에 임상가가 평가하였고 Clinical global impression severity of improvement(CGI-I)로 약물 복용 1주 및 3주에 호전 정도를 평가하였다. 약물 복용 3주에는 약물 복용에 따른 부모 만족도를 설문 조사하였다. 결과 : MPH-OROS의 1일 평균 복용량은 기저선 $25.3{\pm}11.2mg$ 1주 $28.9{\pm}12.7mg$, 3주 $31.3{\pm}13.2mg$이었다. 시간에 따라 용량이 유의하게 증가하였고, 성에 따른 차이는 없었다. 전체의 $13\%$가 중도 탈락했으며, 그 원인으로는 부작용이 가장 많았다. CGI-I의 변화는 시간에 따라 유의하게 감소하는 모습을 보였고, 성에 따른 호전 정도의 차이는 나타나지 않았다. CGI-I에 의한 호전평가에서 MPH-OROS 치료 1주에 호전은 $72.3\%$이고 치료 3주에는 $87.4\%$였다. 한국판 Conners부모용 평가척도 합계 점수는 시간에 따라 유의하게 감소하였다. 한 가지 이상의 부작용을 경험하였던 환자는 119명으로 $20.7\%$에 달하였으며, 가장 많은 빈도로 나타난 것은 식욕부진이고, 불면, 두통, 오심의 순이었다. 기존에 속효성 메틸페니데이트를 사용하던 군과 약물을 처음 사용하는 군을 나누어 부작용 빈도를 살펴보았을 때 크게 차이가 나지 않았다. 부모만족도 설문 결과에서 MPH-OROS 약물치료에 대해 $94\%$의 부모는 전반적으로 만족한다고 응답하였다. 또한 부모가 보고하는 MPH-OROS 의 가장 큰 장점은 오후까지 약물효과 지속, 학교생활 및 수업태도, 가정생활 및 숙제, 과잉행동 개선의 순이었다. 결론 : MPH-OROS는 주의력결핍과잉운동장애의 치료에서 효과적이며 충분히 안전하다.

  • PDF

서울시내 정상 또는 저체중 여중생의 다이어트 행위 실태와 관련요인 분석 (A Study on Dieting Behaviors and Related Factors among Normal or Low-weight Middle School Girls in Seoul)

  • 박선희
    • 한국학교보건학회지
    • /
    • 제14권1호
    • /
    • pp.115-130
    • /
    • 2001
  • Dieting behaviors prevail among most women and are highly increasing among female adolescents who don't have to lose weight. The dieting behaviors of normal or low weight groups are highly related to the negative impact of health risk behaviors. We need a strategy for intervening in the dieting behaviors of relevant groups. With this background, a study was conducted to examine the current situation of dieting behaviors and related factors in middle school girls, and to provide guidelines for the relevant dieting group. This survey was carried out by self-questionnaires passed out to 901 middle school girls from 3 middle schools in Seoul. Data were collected from April 10th, 2000 to April 17th, 2000 and 794 respondents' data were finally selected for analysis. The instruments of this study were Shin's scale for effects of mass-media, Birleson's depression self-rating scale translated by shim, Rosenberg's self-esteem scale, Smilkstein's Family APGAR score translated by Yoon, Kim's school-related adjustment scale. The credibility of instruments was 0.41~0.83 in the pilot study and 0.70~0.86 in the main study. The summary of results was as follows: 1. The general characteristics of respondents were analyzed. In comparison of grade and dieting behaviors, the subjects of the group perceived that their body image was obeser than their real body image and their ideal body image was slenderer than their current body image. A dieter's body image was seriously distorted. 2. The dieting behaviors were analyzed. The Subjects' BMI was within the normal to low range -- they didn't have to lose weight. But actually 47.3% of the respondents were dieters. Their main dieting methods were exercise(71.8%), computer games(64.9%) such as DDR and pump, and intake reduction(64.1%). Most dieters were using desirable methods such as exercise and intake control. But unhealthy methods such as saunax, smoking and harmful drug-use were also used by a few dieters. The main reason for dieting was attractiveness. The chief resources of dieting methods were mass-media(67.8%), friends(64.3%), and parents & relatives(35.1%). Only a few subjects obtained the information from health professionals. While they were trying to lose weight, 42.1% of the subjects experienced side effects such as dizziness(45.0%), apathy(20.5%), appetite loss(18.5%), amenorrhea and the irregularity of the menstrual cycle(16.6%). 3. The relationship between dieting behaviors and factors was analyzed. Dieting behaviors were significantly related to the experience of menarche, the experience of dating with heterosexuals, perceived body image, self-esteem, depression, family's relationship, school instruction-related adjustment, school life-related adjustment, and the effect of mass-media. After that, the multiple logistic regression was used. The analysis revealed that dating, perceived body image, the experience of menarche and the effect of mass media were significant factors. In conclusion, strategies for preventing irrelevant dieting behaviors are urgently required to enhance female adolescents' ability to choose the right information from countless others and to recognize their optimum body image.

  • PDF

RNAi and miRNA in Viral Infections and Cancers

  • Mollaie, Hamid Reza;Monavari, Seyed Hamid Reza;Arabzadeh, Seyed Ali Mohammad;Shamsi-Shahrabadi, Mahmoud;Fazlalipour, Mehdi;Afshar, Reza Malekpour
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권12호
    • /
    • pp.7045-7056
    • /
    • 2013
  • Since the first report of RNA interference (RNAi) less than a decade ago, this type of molecular intervention has been introduced to repress gene expression in vitro and also for in vivo studies in mammals. Understanding the mechanisms of action of synthetic small interfering RNAs (siRNAs) underlies use as therapeutic agents in the areas of cancer and viral infection. Recent studies have also promoted different theories about cell-specific targeting of siRNAs. Design and delivery strategies for successful treatment of human diseases are becomingmore established and relationships between miRNA and RNAi pathways have been revealed as virus-host cell interactions. Although both are well conserved in plants, invertebrates and mammals, there is also variabilityand a more complete understanding of differences will be needed for optimal application. RNA interference (RNAi) is rapid, cheap and selective in complex biological systems and has created new insight sin fields of cancer research, genetic disorders, virology and drug design. Our knowledge about the role of miRNAs and siRNAs pathways in virus-host cell interactions in virus infected cells is incomplete. There are different viral diseases but few antiviral drugs are available. For example, acyclovir for herpes viruses, alpha-interferon for hepatitis C and B viruses and anti-retroviral for HIV are accessible. Also cancer is obviously an important target for siRNA-based therapies, but the main problem in cancer therapy is targeting metastatic cells which spread from the original tumor. There are also other possible reservations and problems that might delay or even hinder siRNA-based therapies for the treatment of certain conditions; however, this remains the most promising approach for a wide range of diseases. Clearly, more studies must be done to allow efficient delivery and better understanding of unwanted side effects of siRNA-based therapies. In this review miRNA and RNAi biology, experimental design, anti-viral and anti-cancer effects are discussed.